{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:59:09Z","timestamp":1783065549837,"version":"3.54.6"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008375","name":"Universit\u00e4t Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40273-021-01023-8","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T01:02:53Z","timestamp":1617238973000},"page":"563-577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland"],"prefix":"10.1007","volume":"39","author":[{"given":"Nadine","family":"Schur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Gudala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umakanth","family":"Vudumula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreelatha","family":"Vadapalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1220-0731","authenticated-orcid":false,"given":"Arjun","family":"Bhadhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Adlard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schwenkglenks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"issue":"9648","key":"1023_CR1","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502\u201317.","journal-title":"Lancet"},{"key":"1023_CR2","unstructured":"National Multiple Sclerosis Society. Types of MS: relapsing-remitting MS; 2019. https:\/\/www.nationalmssociety.org\/What-is-MS\/Types-of-MS\/Relapsing-remitting-MS (Accessed 20 Mar 2021)."},{"issue":"3","key":"1023_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1177\/1352458507084264","volume":"14","author":"H Tremlett","year":"2008","unstructured":"Tremlett H, Yinshan Z, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler. 2008;14(3):314\u201324.","journal-title":"Mult Scler"},{"key":"1023_CR4","unstructured":"OFSEP. Description of OFSEP cohort; 2018. http:\/\/www.ofsep.org\/fr\/la-cohorte-ofsep\/descriptif-de-la-cohorte (Accessed 20 Mar 2021)."},{"issue":"15","key":"1023_CR5","first-page":"4","volume":"90","author":"V Khurana","year":"2018","unstructured":"Khurana V, Sharma H, Medin J. Estimated prevalence of secondary progressive multiple sclerosis in the USA and Europe: results from a systematic literature search. Neurology. 2018;90(15):4.","journal-title":"Neurology"},{"key":"1023_CR6","first-page":"w14623","volume":"148","author":"MA Puhan","year":"2018","unstructured":"Puhan MA, Steinemann N, Kamm CP, Muller S, Kuhle J, Kurmann R, et al. A digitally facilitated citizen-science driven approach accelerates participant recruitment and increases study population diversity. Swiss Med Wkly. 2018;148:w14623.","journal-title":"Swiss Med Wkly"},{"issue":"Pt 10","key":"1023_CR7","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1093\/brain\/aws246","volume":"135","author":"M Calabrese","year":"2012","unstructured":"Calabrese M, Poretto V, Favaretto A, Alessio S, Bernardi V, Romualdi C, et al. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain. 2012;135(Pt 10):2952\u201361.","journal-title":"Brain"},{"key":"1023_CR8","unstructured":"Institute for Clinical and Economic Review. Siponimod for the treatment of secondary progressive multiple sclerosis: effectiveness and value; 2019."},{"key":"1023_CR9","unstructured":"Federal Office of Public Health. Spezialit\u00e4tenliste (SL); 2019. http:\/\/www.spezialitaetenliste.ch (Accessed 20 Mar 2021)."},{"key":"1023_CR10","unstructured":"Compendium.ch\u00ae. https:\/\/compendium.ch\/ (Accessed 20 Mar 2021)."},{"issue":"5","key":"1023_CR11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","volume":"167","author":"P Gergely","year":"2012","unstructured":"Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167(5):1035\u201347.","journal-title":"Br J Pharmacol"},{"key":"1023_CR12","unstructured":"Bar-Or A, Derfuss T, Vermersch P, editors. Longitudinal changes in lymphocyte subsets of siponimod-treated patients with SPMS. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis\u2014Americas Committee for Treatment and Research in Multiple Sclerosis Meeting, 25\u201328 October 2017, Paris."},{"key":"1023_CR13","unstructured":"Sarr C, Savelieva M, Ette G, editors. Modeling dose-PK-lymphocytes relationship under siponimod (BAF312) treatment to infer time to immune reconstitution [poster]. Presented at the 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis\u2014European Committee for Treatment and Research in Multiple Sclerosis Meeting, 10\u201313 September 2014; Boston (MA)."},{"key":"1023_CR14","doi-asserted-by":"crossref","unstructured":"Bigaud M, Nuesslein-Hildesheim B, Tran T, editors. Siponimod is a functional agonist for the S1P5 receptor [poster]. Presented at the 70th Annual American Academy of Neurology Annual Meeting, 21\u201327 April 2018, Los Angeles (CA).","DOI":"10.1212\/WNL.90.15_supplement.P3.404"},{"issue":"1","key":"1023_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12974-016-0686-4","volume":"13","author":"A Gentile","year":"2016","unstructured":"Gentile A, Musella A, Bullitta S, Fresegna D, De Vito F, Fantozzi R, et al. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflammation. 2016;13(1):207.","journal-title":"J Neuroinflammation"},{"key":"1023_CR16","unstructured":"Zalc B, editor. Impact of siponimod (BAF 312) on CNS remyelination in a transgenic Xenopus model [poster]. Presented at the 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis\u2014European Committee for Treatment and Research in Multiple Sclerosis Meeting, 10\u201313 September 2014, Boston (MA)."},{"key":"1023_CR17","doi-asserted-by":"crossref","unstructured":"Deogracias R, Schubart A, Barde Y-A, editors. Siponimod increases brain-derived neurotrophic factor (BDNF) levels in cortical neuronal cultures and na\u00efve healthy mice [poster]. Presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 10\u201312 October 2018, Berlin.","DOI":"10.26226\/morressier.5b719e465aff74008ae4ca8c"},{"issue":"10127","key":"1023_CR18","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263\u201373.","journal-title":"Lancet"},{"key":"1023_CR19","doi-asserted-by":"crossref","unstructured":"Kappos L, Giovannoni G, Gold R, Fox RJ, Vermersch P, Benedict RH, et al. Long-term efficacy and safety of siponimod in patients with SPMS: EXPAND extension analysis up to 5 years (4128). AAN Enterprises; 2020.","DOI":"10.1212\/WNL.94.15_supplement.4128"},{"issue":"7","key":"1023_CR20","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1080\/03007995.2020.1747999","volume":"36","author":"IA Samjoo","year":"2020","unstructured":"Samjoo IA, Worthington E, Haltner A, Cameron C, Nicholas R, Rouyrre N, et al. Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis. Curr Med Res Opin. 2020;36(7):1157\u201366.","journal-title":"Curr Med Res Opin"},{"issue":"2 Suppl","key":"1023_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/1352458517708685","volume":"23","author":"P Calabrese","year":"2017","unstructured":"Calabrese P, Kobelt G, Berg J, Capsa D, Eriksson J. European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: results for Switzerland. Mult Scler. 2017;23(2 Suppl):192\u2013203.","journal-title":"Mult Scler."},{"key":"1023_CR22","unstructured":"National Institute for Health and Care Excellence (NICE). Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis; 2007. https:\/\/www.nice.org.uk\/guidance\/ta127\/history (Accessed 20 Mar 2021)."},{"issue":"4","key":"1023_CR23","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3111\/13696998.2015.1135805","volume":"19","author":"J Mauskopf","year":"2016","unstructured":"Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. J Med Econ. 2016;19(4):432\u201342.","journal-title":"J Med Econ"},{"issue":"4","key":"1023_CR24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1600-0404.1982.tb03084.x","volume":"65","author":"U Patzold","year":"1982","unstructured":"Patzold U, Pocklington PR. Course of multiple sclerosis: first results of a prospective study carried out of 102 MS patients from 1976\u20131980. Acta Neurol Scand. 1982;65(4):248\u201366.","journal-title":"Acta Neurol Scand"},{"key":"1023_CR25","unstructured":"Swiss Federal Office of Statistics. Geburten und Todesf\u00e4lle; 2018. https:\/\/www.bfs.admin.ch\/bfs\/de\/home\/statistiken\/bevoelkerung\/geburten-todesfaelle.html (Accessed 20 Mar 2021)."},{"issue":"2","key":"1023_CR26","first-page":"101","volume":"29","author":"RJ Pokorski","year":"1997","unstructured":"Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med. 1997;29(2):101\u20136.","journal-title":"J Insur Med."},{"key":"1023_CR27","unstructured":"National Institute for Health and Care Excellence (NICE). Ocrelizumab for treating relapsing multiple sclerosis [TA533]; 2018. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10152\/documents (Accessed 20 Mar 2021)."},{"key":"1023_CR28","doi-asserted-by":"crossref","unstructured":"Secondary progressive efficacy clinical trial of recombinant interferon-beta-1a in MSSG. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology. 2001;56(11):1496\u2013504.","DOI":"10.1212\/WNL.56.11.1496"},{"key":"1023_CR29","doi-asserted-by":"crossref","unstructured":"Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J, Group MS, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123\u201336.","DOI":"10.1177\/1352458517694432"},{"issue":"1","key":"1023_CR30","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1524-4733.2006.00144.x","volume":"10","author":"M Orme","year":"2007","unstructured":"Orme M, Kerrigan J, Tyas D, Russell N, Nixon R. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health. 2007;10(1):54\u201360.","journal-title":"Value Health"},{"key":"1023_CR31","unstructured":"Swiss Federal Office of Statistics. Landesindex der Konsumentenpreise; 2019. https:\/\/www.bfs.admin.ch\/bfs\/de\/home\/statistiken\/preise\/landesindex-konsumentenpreise.html (Accessed 20 Mar 2021)."},{"key":"1023_CR32","unstructured":"FMH Swiss Medical Association. TARMED-Tarifbrowser Version 01.09.00_BR_KVG; 2018. https:\/\/www.fmh.ch\/ambulante_tarife\/tarmed-tarif\/tarmed_tarifbrowser-datenbank.html (Accessed 20 Mar 2021)."},{"key":"1023_CR33","unstructured":"Swiss Federal Office of Public Health. Analysenliste Version vom 01.03.2019; 2019. https:\/\/www.bag.admin.ch\/bag\/de\/home\/versicherungen\/krankenversicherung\/krankenversicherung-leistungen-tarife\/Analysenliste.html (Accessed 20 Mar 2021)."},{"key":"1023_CR34","unstructured":"Datenspiegel SwissDRG 6.0; 2019. https:\/\/datenspiegel60.swissdrg.org\/ (Accessed 20 Mar 2021)."},{"key":"1023_CR35","unstructured":"National Institute for Health and Care Excellence (NICE). Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis; 2012. https:\/\/www.nice.org.uk\/guidance\/ta254 (Accessed 20 Mar 2021)."},{"key":"1023_CR36","unstructured":"National Institute for Health and Care Excellence, 2020. Siponimod for treating secondary progressive multiple sclerosis. https:\/\/www.nice.org.uk\/guidance\/TA656 (Accessed 8 Dec 2020)."},{"issue":"5","key":"1023_CR37","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/jnnp.2003.010090","volume":"75","author":"O Andersen","year":"2004","unstructured":"Andersen O, Elovaara I, Farkkila M, Hansen HJ, Mellgren SI, Myhr KM, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2004;75(5):706\u201310.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1023_CR38","first-page":"CD005181","volume":"1","author":"L La Mantia","year":"2012","unstructured":"La Mantia L, Vacchi L, Di Pietrantonj C, Ebers G, Rovaris M, Fredrikson S, et al. Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst Rev. 2012;1:CD005181.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01023-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-021-01023-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01023-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T08:03:00Z","timestamp":1724745780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-021-01023-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1023"],"URL":"https:\/\/doi.org\/10.1007\/s40273-021-01023-8","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"17 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Novartis Pharma Schweiz AG, including research funding received by Matthias Schwenkglenks via Universit\u00e4t Basel. Open Access funding was provided by Universit\u00e4t Basel (Universit\u00e4tsbibliothek Basel).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Alain Casanova is an employee of Novartis Pharma Schweiz AG, Nicholas Adlard is an employee of Novartis Pharma AG, and\u00a0Kapil Gudala, Umakanth Vudumula and Sreelatha Vadapalle are employees of Novartis Healthcare Private Limited.\u00a0Matthias Schwenkglenks received research funding from Novartis Pharma Schweiz AG, via Universit\u00e4t Basel.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No specific ethical approval was obtained for this study, as the present economic model did not involve the recruitment of human or animal subjects or the collection of research samples.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A request for the Excel models can be made to the corresponding author but is not guaranteed because of copyright. Acceptance of the request is subject to approval from Novartis Pharma AG.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AC, NS and MS conceptualised the study. KG, NA, and UV produced the underlying cost-effectiveness model. KG, NA and SV produced the underlying budget impact model. NS completed the cost-effectiveness adaptation and AB completed the budget impact adaptation. NS and AB drafted the manuscript. AC organised and led meetings with Swiss clinical experts, provided methodological guidance to estimate parameters and undertook primary research to estimate market shares in Switzerland. All authors contributed to interpreting the results and critically reviewed and edited the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}